References
- Biben, J. A., Atmodiwirjo, P. (2019). Free flap thrombosis in patients with hypercoagulability: A systemic review. Arch. Plastic Surg.,46, 572–579.10.5999/aps.2019.00738
- Dählback, B. (2008). Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood, 112 (1), 19–27.10.1182/blood-2008-01-077909
- Dahlbäck, B. (2005). Blood coagulation and its regulation by anticoagulant pathways: Genetic pathogenesis of bleeding and thrombotic diseases. J. Int. Med.,257, 209–223.10.1111/j.1365-2796.2004.01444.x
- Dizon-Towson, D., Nelson, L., Jang, H. (1997). The incidence of the factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis. Amer. J. Obstet. Gynecol., 176, 883–886.10.1016/S0002-9378(97)70615-X
- Drizlionoka, K., Ozoliņa, A., Ņikitina-Zaķe, L., Mamaja, B. (2019). Markers for thrombosis prediction in free flap surgery. Eur. J. Anaesthesiol. E-Supplement, Abstract No.12AP04-3, Vol. 36, Suppl. 57.
- Drizlionoka, K., Zarinš, J., Ozolina, A., Nikitina-Zake, L., Mamaja, B. (2019). Polymorphism rs2066865 in the Fibrinogen Gamma Chain (FGG) gene increases plasma fibrinogen concentration and is associated with an increased microvascular thrombosis rate. Medicina,55, 563.10.3390/medicina55090563678097231484330
- El-Galaly, T. C., Severinsen, M., Overvad, K., Steffensen, R., Vistisen, A. K., Tjønneland, A., Kristensen, S. R. (2013). Single nucleotide polymorphisms and the risk of venous thrombosis: Results from a Danish case-cohort study. Brit. J. Haemat., 160, 838–841.10.1111/bjh.1213223150947
- Falcon, C. R., Cattaneo, M., Panzeri, D., Martinelli, I., Mannucci, P. M. (1994). High prevalence of hyperhomocysteinemia in patients with juvenile venous thrombosis. Atheroscl. Thromb. Vasc. Biol.,14, 1080–1083.
- Farrell, D. H. (2012). γ’ Fibrinogen as a novel marker of thrombotic disease. Clin. Chem. Lab. Med.,50, 1903–1909.10.1515/cclm-2012-000523091268
- Friedman, T., Coon, D. B., Micheals, J. V., Bontempo, F., Young, V. L., Clavijo, J. A., Rubin, J. P. (2010). Hereditery coagulopathies: Practical diagnosis and management for the plastic surgeon. Plastic Reconstr. Surg.,5, 1544–1552.10.1097/PRS.0b013e3181d5134420440173
- Henschen, A., Lottspeich, F., Kehl, M., Southan, C. (1983). Covalent structure of fibrinogen. Ann. NY Acad. Sci., 408, 28–43.10.1111/j.1749-6632.1983.tb23232.x6575689
- Liew, S. C., Gupta, E. D. (2015). Methylenetetrahydrofolate reductase (MTHFR) C667T polymorphism: Epidemiology, metabolism and the associated diseases. Eur. J. Med. Gen., 58, 1–10.10.1016/j.ejmg.2014.10.00425449138
- Livak, K. J. (1999). Allelic discrimination using fluorogenic probes and the 5’nuclease assay. Genet. Anal.,14, 143–149.10.1016/S1050-3862(98)00019-9
- van der Meer, J., Stoepman-van Dalen, E. A., Jansen, J. M. S. (1973). Antithrombin-III deficiency in a Dutch family. J. Clin. Pathol., 26 (7), 532–538.10.1136/jcp.26.7.532
- Meltzer, M. E., Lisman, T., de Groot, P. G., Meijers, M. C., le Cessie,S., Doggen, C. J., Rosendaal, F. R. (2010). Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood.,116, 113–121.10.1182/blood-2010-02-267740
- Pannuci, C. J., Kovach, S. J., Cuker, A. (2015). Microsurgery and hypercoagulable state. A haematologist perspective. Plast. Reconstr. Surg.,4, 545–552.10.1097/PRS.0000000000001591
- Pathare, A., Alkindi, S., Albalushi, T., Bayoumi, R., Dennisoni, D., Muralitharan, S. (2004). Heterozygous methylene tetrahydrofolate reductase mutation with mild hyperhomocysteinemia associated with deep vein thrombosis. Clin. Lab. Haem.,26, 143–146.10.1111/j.1365-2257.2004.00585.x
- Patnaik, M. M., Moll, S. (2008). Inherited antithrombin deficiency: A review. Haemophilia, 14 (6), 1229–1239.10.1111/j.1365-2516.2008.01830.x
- Poort, S. R., Rosendaal, F. R., Reitsma, P. H., Bertina, R. M. (1996). A common genetic variation in the 3’- untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood,88, 3698–3703.10.1182/blood.V88.10.3698.bloodjournal88103698
- Ray, J. G., Shmorgun, D., Chan, W. S. (2002). Common C677T polymorphism of the methylene tetrahydrofolate reductase gene and the risk of venous thromboembolism: Metaanalysis of 31 studies. Pathophysiol. Haemost. Thromb., 32, 51–58.10.1159/000065076
- Rees, D., Cox, M., Clegg, J. (1995). World distribution of factor V Leiden. Lancet,346, 1133–1134.10.1016/S0140-6736(95)91803-5
- Ridker, P. M., Glynn, R., Miletich, J. (1997). Age specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann. Intern. Med.,126, 528–531.10.7326/0003-4819-126-7-199704010-000059092318
- Ridker, P. M., Miletich, J. P., Hennekens, C. H., Buring, J. E. (1997). Ethnic distribution of factor V Leiden in 4047 men and women: Implications for venous thromboembolism screening. JAMA, 277, 1305–1307.10.1001/jama.1997.03540400055031
- Rosenberg, N., Murata, M., Ikeda, Y., Opare-Sem, O., Zivelin, A., Geffen, E. (2002). The frequent 5, 10-methylenetetrahydrofolate reductase C667T polymorphism is associated with common haplotype in Whites, Japanese and Africans. Amer. J. Hum. Genet., 70, 758–762.10.1086/33893238495211781870
- Rosendaal, F. R., Doggen, C. J. M., Zivelin, A., Arruda, V. R., Aiach, M., Siscovick, D. S., Hillarp, A., Watzke, H. H., Bernardi, F., Cumming, A. M., Preston, F. E., Reitsma, P. H. (1998). Geographic distribution of the 20210 G to a prothrombin variant. Thromb. Haemost., 79, 706–708.10.1055/s-0037-1615049
- Rosendaal, F. R., Koster T., Vandenbroucke J., Reitsma P. (1995). High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood, 85, 1504–1508.10.1182/blood.V85.6.1504.bloodjournal8561504
- Rozen, R. (1997). Genetic predisposition to hyperhomocysteinaemia: Deficiency of methylenetetrahydrofolate reductase (MTHFR). Thromb Haemost.,78, 523–536.
- Slavik, L., Krcova, V., Hlusi, A., Prochazkova, J., Prochazka, M., Ulehlova, J., Indrak K. (2009). Molekular pathophysiology of thrombotic states and their impact to laboratory diagnostics. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub., 153 (1), 19–26.10.5507/bp.2009.00319365521
- Segers, K., Dahlbäck, B., Nicolaes, G. (2007). Coagulation factor V and thrombophilia: Background and mechanisms. Thromb. Haemost., 98, 530–542.10.1160/TH07-02-0150
- Stanger, O., Herrman, W., Pietrzik, K., Fowler, B., Giesel, J., Dierkes, J. (2004). Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases. Z. Kardiol., 93, 439–453.10.1007/s00392-004-0075-315252738
- Svensson, P., Dahlbäck, B. (1994). Resistance to activated protein C as a basis for venous thrombosis. New Engl. J. Med., 330 (8), 517–522.10.1056/NEJM1994022433008018302317
- Undas, A., Casini, A. (2019). Congenital structural and functional fibrinogen disorders: A primer for internists. Pol. Arch. Intern. Med., 129 (12), 913–920.10.20452/pamw.1508231797863
- Welsch, G., Upchurch, G., Loscalzo, J. (1997). Hyperhomocysteinaemia and atherothrombosis. Ann. NY Acad. Sci., 81, 48–58.10.1111/j.1749-6632.1997.tb51988.x9186584
- Vanags, I., Stepanovs, J., Ozolina, A., Mukans, M., Bjertnaes, L. J., Mamaja, B. (2020). Thromboelastometry for assessing risks of free flap thrombosis in patients undergoing microvascular surgery. Front. Med.,7, 289.10.3389/fmed.2020.00289
- Xuan, C., Bai, X. Y., Gao, G., Yang, Q., He, G. W. (2011). Association between polymorphism methylenetetrahydrofolate reductase (MTHFR) C677T and risk of myocardial infarction: A meta-analysis for 8,140 cases and 10,522 controls. Arch. Med. Res.,42, 677–685.10.1016/j.arcmed.2011.11.009
- Zöller, B., Dahlbäck, B. (1994). Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet, 343, 1536–1538.10.1016/S0140-6736(94)92940-8
- Zöller, B., Garcia de Frutos, P., Hillarp, A., Dählback, B. (1999). Thrombophilia as a multigenic disease. Haematologica,84, 59–70.